IBT’s Clinical Phase III study of the drug candidate IBP-9414 for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in premature infants, the Connection Study, started in
“Currently, we do not expect any safety signals to occur at the 600 patient review, as the DMC recently looked at 571 patients corresponding to approximately 25,000 patient days. In addition, it is good to see that recruitment is many times greater than observed during the spring of 2021. We also see that centers are motivated to accelerate recruitment in order to develop a pharmaceutical-grade-probiotic for the prevention of NEC and improving feeding tolerance in preterm infants.” says Staffan CEO, IBT.
About
IBT is currently developing the drug candidate IBP-9414. The ambition for IBP-9414 is to become the world’s first approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfill unmet needs for diseases where there are currently no prevention or treatment therapies available.
For additional information please contact
Staffan Strömberg, CEO
Bryggargatan 10
111 21 Stockholm
Phone: +46 8 410 145 55
info@ibtherapeutics.com
www.ibtherapeutics.com
Publication
This information is information that
The information was submitted for publication, through the agency of the contact persons set out above, at 19.00 CET on
Attachment
- PR 20210930 600 pat ENG
© OMX, source